Sponsor

S.LAB (SOLOWAYS)

Clinical research sponsor

Published trials11
Recruiting shown0
Roles1
SourceClinicalTrials.gov

Clinical trials

11 shown
Clinical Trial Protocol: Randomized Placebo-Controlled Pilot Study of GcMAF (Soloways TM) in Patients With Metastatic Breast CancerNCT06434077 · lead sponsor · 2025-08-20
NOT_YET_RECRUITING
Comparative Efficacy of Metformin and Berberine Among TCF7L2 (rs7903146) TT vs. CC Genotype Carriers With Type 2 DiabetesNCT06911983 · lead sponsor · 2025-07-01
NOT_YET_RECRUITING
EF-M2 (Immutalon) Multiple Ascending Dose Study in Moderate-to-Severe Rheumatoid ArthritisNCT07349420 · lead sponsor · 2025-06-03
COMPLETED
Integrative Group Psychotherapy (Terebenin's Method) in Adults With Subclinical and Mild/Moderate Anxiety and DepressionNCT06863948 · lead sponsor · 2024-05-30
COMPLETED
A Pilot Study of Berberine (Soloways ™) in Patients with Type 2 Diabetes Mellitus Carrying TCF7L2 PolymorphismsNCT06863922 · lead sponsor · 2024-05-03
COMPLETED
Personalized Management of Type 2 Diabetes Using AI-Guided (GenAIS TM) Dietary SupplementationNCT06469658 · lead sponsor · 2024-02-02
COMPLETED
Evaluating the Efficacy of AI-Guided (GenAIS TM) vs. Standard Physician-Guided Dietary Supplement Prescriptions for Weight Loss in Obese PatientsNCT06458296 · lead sponsor · 2024-02-02
COMPLETED
The Impact of Oral Glutathione on Oxidative Damage and Glycated Hemoglobin (HbA1c) Levels in Type 2 Diabetes PatientsNCT06313164 · lead sponsor · 2023-06-20
COMPLETED
Preventing Weight Regain Post-Semaglutide Treatment With Active Fiber Supplement (Soloways)NCT06221696 · lead sponsor · 2023-06-12
COMPLETED
Effectiveness and Safety of Semaglutide Combined With Dietary Fiber (Soloways) in Adults With Overweight or ObesityNCT06215196 · lead sponsor · 2023-04-14
COMPLETED
Efficacy of Dietary Fiber Supplementation (Soloways) in Patients With Specific Genetic PolymorphismsNCT06188832 · lead sponsor · 2022-03-02
COMPLETED

Sponsor roles

lead sponsor11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.